Reuters logo
Novartis cancer drug Kisqali succeeds in late-stage trial
November 8, 2017 / 6:39 AM / a month ago

Novartis cancer drug Kisqali succeeds in late-stage trial

ZURICH, Nov 8 (Reuters) - Novartis drug Kisqali was shown effective in a late-stage trial in treating advanced or metastatic breast cancer, the Swiss drugmaker said on Wednesday.

In the so-called MONALEESA-7 trial, Kisqali (ribociclib) combination therapy met its primary endpoint of progression-free survival in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. This demonstrated superior efficacy of Kisqali combination therapy versus endocrine treatment alone, it said.

Novartis in August said Kisqali won European Union approval as first-line treatment for a tough-to-treat breast cancer, bolstering the drugmaker’s bid to challenge U.S. rival Pfizer’s Ibrance. (Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below